GSK Completes £1.2 Billion Sale of Remaining Haleon Stake

The pharmaceutical giant exits its consumer healthcare business to focus on core areas like vaccines and infectious diseases.

GSK raised a total of £3.9 billion from selling its Haleon shares since the 2022 demerger.
The final 4.2% stake was sold at 324p per share, close to Haleon's IPO price.
Haleon was created in 2019 from the merger of GSK and Pfizer's consumer healthcare units.
Pfizer still retains a 24% stake in Haleon, while GSK has fully exited.
Haleon is undergoing restructuring, including closing its UK manufacturing site and selling off non-core brands.